

Population pharmacokinetics and exposure-response in non-small cell lung cancer

British Journal of Clinical Pharmacology

83, 1216-1226

DOI: [10.1111/bcp.13223](https://doi.org/10.1111/bcp.13223)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1216-1226.	1.1	96
2	Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , 2017, 12, 555-562.	1.7	41
3	Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 321-330.	1.3	46
4	Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 2138-2147.	3.2	21
5	The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1156-1169.	1.1	47
6	Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats. <i>Xenobiotica</i> , 2018, 48, 1106-1112.	0.5	16
7	The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer and in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 474-484.	1.0	41
8	Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 504-513.	1.0	20
9	Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2877-2888.	1.1	20
10	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. <i>Pharmacogenomics</i> , 2018, 19, 727-740.	0.6	20
11	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 158, 174-183.	1.4	50
12	Development and validation of a UPLC-MS/MS method for quantification of osimertinib (AZD9291) and its metabolite AZ5104 in human plasma. <i>Biomedical Chromatography</i> , 2018, 32, e4365.	0.8	19
13	<p></p>Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5467-5484.	1.0	36
14	FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring, and Management. <i>Biomolecules</i> , 2019, 9, 668.	1.8	80
15	Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 112-124.	2.0	11
16	Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1309-1318.	0.8	62
17	Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 369, 291-299.	1.3	13
18	Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1099-1109.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 142-159.	1.0	9
20	Efficacy and safety of osimertinib in treating EGFR-mutated advanced NSCLC: A meta-analysis. <i>International Journal of Cancer</i> , 2019, 145, 284-294.	2.3	52
21	Absolute Bioavailability of Osimertinib in Healthy Adults. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 198-207.	0.8	22
22	Drug Exposure to Establish Pharmacokinetic-Response Relationships in Oncology. <i>Clinical Pharmacokinetics</i> , 2020, 59, 123-135.	1.6	5
23	Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. <i>Journal of Thoracic Oncology</i> , 2020, 15, 637-648.	0.5	83
24	Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 33-44.	1.0	25
25	The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 777-785.	1.2	40
26	Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results. <i>Biomedical Chromatography</i> , 2020, 34, e4771.	0.8	16
27	Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib. <i>Lung Cancer</i> , 2020, 150, 26-35.	0.9	11
28	Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-MS/MS Assay. <i>Cancers</i> , 2020, 12, 1897.	1.7	14
29	Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancers</i> , 2020, 12, 3179.	1.7	11
30	The impact of age and performance status on the efficacy of osimertinib in patients with EGFR T790M-positive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 153-155.	0.6	2
31	MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers. <i>Cancer</i> , 2020, 126, 3788-3799.	2.0	26
32	Characterizing Exposure-Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1156-1170.	2.3	47
33	A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00613.	1.1	6
34	Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 441-464.	0.8	110
35	An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 809-819.	0.9	4
37	An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 772-779.	1.0	9

#	ARTICLE	IF	CITATIONS
38	Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 3697.	5.8	14
39	Simultaneous and rapid determination of 12 tyrosine kinase inhibitors by LC-MS/MS in human plasma: Application to therapeutic drug monitoring in patients with non-small cell lung cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1175, 122752.	1.2	24
41	A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 728155.	1.3	9
43	Precision Dosing of Targeted Therapies Is Ready for Prime Time. <i>Clinical Cancer Research</i> , 2021, 27, 6644-6652.	3.2	21
44	Osimertinib plus platinum+/-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study. <i>ESMO Open</i> , 2021, 6, 100271.	2.0	40
45	Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1 mutant advanced hematologic malignancies. <i>Clinical and Translational Science</i> , 2021, 14, 942-953.	1.5	8
46	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Lung Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019, 14, 242-257.	0.8	5
47	Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib. <i>Cancers</i> , 2021, 13, 6.	1.7	30
48	The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET. <i>American Journal of Cancer Research</i> , 2020, 10, 3316-3327.	1.4	2
49	Defining the Sensitivity Landscape of 74,389 EGFR Variants to Tyrosine Kinase Inhibitors. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
50	Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry. <i>Clinica Chimica Acta</i> , 2022, 527, 1-10.	0.5	8
52	Relationship between Biodistribution and Tracer Kinetics of 11C-Erlotinib, 18F-Afatinib and 11C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2022, 12, 883.	1.3	6
53	Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022, 1199, 123245.	1.2	5
54	Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice. <i>Targeted Oncology</i> , 2022, 17, 53-59.	1.7	1
55	Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer. <i>Drugs</i> , 2022, 82, 15-32.	4.9	3
56	Osimertinib-Centered Therapy Against Uncommon Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer- A Mini Review. <i>Frontiers in Oncology</i> , 2022, 12, 834585.	1.3	1
57	Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 327-334.	2.3	7
58	Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences. <i>Cancer Investigation</i> , 2022, 40, 590-603.	0.6	5

#	ARTICLE	IF	CITATIONS
59	Comparison of a newly developed high performance liquid chromatography method with diode array detection to a liquid chromatography tandem mass spectrometry method for the quantification of cabozantinib, dabrafenib, nilotinib and osimertinib in human serum â€“ Application to therapeutic drug monitoring. <i>Clinical Biochemistry</i> , 2022, 105-106, 35-43.	0.8	3
60	Improving the tolerability of osimertinib by identifying its toxic limit. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211032.	1.4	16
61	Development and Optimization of Osimertinib-loaded Biodegradable Polymeric Nanoparticles Enhance In-vitro Cytotoxicity in Mutant EGFR NSCLC Cell Models and In-vivo Tumor Reduction in H1975 Xenograft Mice Models. <i>AAPS PharmSciTech</i> , 2022, 23, .	1.5	4
62	Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS. <i>Molecules</i> , 2022, 27, 4474.	1.7	5
63	Nazartinib for treatment-naïve EGFR-mutant nonâ€™small cell lung cancer: Results of a phase 2, single-arm, open-label study. <i>European Journal of Cancer</i> , 2022, 172, 276-286.	1.3	4
64	Allele-specific activation, enzyme kinetics, and inhibitor sensitivities of EGFR exon 19 deletion mutations in lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	9
65	Analysis of adverse drug reactions of Osimertinib in the 2ndâ€™line treatment of <scp>EGFR</scp> mutant advanced nonsmall cell lung cancer. <i>Precision Medical Sciences</i> , 2022, 11, 69-81.	0.1	1
66	Exposureâ€™Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting. <i>Pharmaceutical Research</i> , 2022, 39, 2507-2514.	1.7	8
67	Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial. <i>Lung Cancer</i> , 2022, 171, 97-102.	0.9	7
69	Exposureâ€™Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Pharmaceutics</i> , 2022, 14, 1844.	2.0	12
70	Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2022, 40, 1254-1262.	1.2	4
71	Defining the sensitivity landscape of EGFR variants to tyrosine kinase inhibitors. <i>Translational Research</i> , 2023, 255, 14-25.	2.2	8
72	Effects of food and race on the pharmacokinetics of lazertinib in healthy subjects and patients with EGFR mutation-positive advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2023, 175, 112-120.	0.9	1
73	Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. <i>Investigational New Drugs</i> , 2023, 41, 122-133.	1.2	6
74	The metabolism and pharmacokinetic study of deuterated osimertinib. <i>Biopharmaceutics and Drug Disposition</i> , 0, , .	1.1	0
75	Simultaneous online SPE-HPLC-MS/MS quantification of gefitinib, osimertinib and icotinib in dried plasma spots: Application to therapeutic drug monitoring in patients with non-small cell lung cancer. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2023, , 115275.	1.4	1
76	Pharmacokinetic and doseâ€™finding study of osimertinib in patients with impaired renal function and low body weight. <i>Cancer Science</i> , 2023, 114, 2087-2097.	1.7	6
77	Understanding the Risk of Drug Interactions Between Ritonavir-Containing COVID-19 Therapies and Small-Molecule Kinase Inhibitors in Patients With Cancer. <i>JCO Precision Oncology</i> , 2023, , .	1.5	0

#	ARTICLE	IF	CITATIONS
78	Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 679-690.	1.9	0
81	Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. <i>Clinical Pharmacokinetics</i> , 2023, 62, 1333-1364.	1.6	4